Ispire Reports Q2 Revenue of $20.3M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
Should l Buy ISPR?
Sees Q2 revenue $20.3M vs. $41.8M last year. "This quarter represented an inflection point for Ispire during its yearlong cost cutting and customer quality rationalization efforts and we believe future quarters will see top line growth, consistent cash flows and bottom-line improvement. We are confident we have laid a solid foundation for future success," commented Michael Wang, Co-CEO of Ispire. "During the second quarter of fiscal 2026, we maintained our focus on prioritizing high-quality revenue, and reinforcing our disciplined and intentional approach to sustainable growth. This was particularly evident in our efforts to reduce net accounts receivable, which continues to have strong success. Over the second fiscal quarter we reduced net accounts receivable by 19.5% to $37.9M, compared to $47.0M at the end of FY25."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISPR
Wall Street analysts forecast ISPR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.205
Low
6.50
Averages
6.50
High
6.50
Current: 2.205
Low
6.50
Averages
6.50
High
6.50
About ISPR
Ispire Technology Inc. is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded and non-branded e-cigarettes and vaping hardware products in both the nicotine and cannabis spaces. The Company’s nicotine products are marketed under the Aspire brand name, primarily through a global distribution network. It sells its cannabis vaping hardware in the United States, Canada, South Africa, and Germany. Its cannabis products are marketed under the Ispire brand name, primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies, including multi- and single-state operators, brand owners, and co-packers. Its product portfolio includes E-Cigarette Products and Cannabis Products. The Company's open system devices are marketed under brands such as Nautilus and Zestquest and closed system products are marketed under licensed brands including BRKFST and Hidden Hills Club.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ispire Technology to Participate in 38th Annual ROTH Conference
- Conference Participation: Ispire Technology will participate in the 38th Annual ROTH Conference from March 22-24, 2026, in Dana Point, California, showcasing its innovations in vaping technology and precision dosing.
- Management Team Engagement: The company's management team will hold a fireside chat on March 23 at 8:00 a.m. PT in Blue-Consumer-Salon 2, aiming to engage with investors on the company's strategic development and market outlook.
- Global Patent Portfolio: Ispire owns or has filed over 200 patents globally, covering the research, development, and commercialization of e-cigarettes and cannabis vaping products, highlighting its technological leadership in the industry.
- Market Expansion Plans: Ispire's tobacco products are marketed worldwide, and the company has recently commenced marketing activities in Canada and Europe, further expanding its international market share.
See More
Ispire Technology to Participate in 38th Annual ROTH Conference
- Management Participation: Ispire Technology's management team will participate in the 38th Annual ROTH Conference from March 22-24, 2026, in Dana Point, California, showcasing innovations in vaping technology and precision dosing to enhance the company's visibility and credibility among investors.
- Fireside Chat Details: The management team will hold a fireside chat on March 23, 2026, at 8:00 a.m. PT, providing a direct interaction opportunity with investors, thereby strengthening communication and connections with potential investors.
- Global Patent Portfolio: Ispire owns or has filed over 200 patents related to the research, development, and commercialization of e-cigarettes and cannabis vaping products, indicating the company's technological leadership in the industry and laying the groundwork for future market expansion.
- Market Expansion Plans: Ispire's tobacco products are marketed globally, with restrictions in the U.S., China, and Russia, yet the company has initiated marketing activities in Canada and Europe, demonstrating a proactive approach to its internationalization strategy.
See More
Hospital and Medical Practitioners Stocks Decline
- Market Underperformance: On Tuesday, hospital and medical practitioners' stocks collectively fell by approximately 1.2%, indicating a decline in market confidence in the sector, which could negatively impact long-term investor expectations.
- AdaptHealth Leads Decline: AdaptHealth's stock plummeted by about 13.6%, making it the worst performer in the industry, suggesting potential operational or financial challenges that could affect its market share.
- Centene Pressured: Centene's stock decreased by approximately 3.5%, and although the drop is smaller, it still reflects market concerns regarding its future growth, potentially prompting investors to reassess their investment strategies.
- Industry Trend Warning: The overall decline in the healthcare sector may signal broader economic issues, prompting investors to monitor relevant policy changes and market dynamics to adjust their portfolios accordingly.
See More
Ispire Technology Q2 Earnings Report Analysis
- Poor Earnings Performance: Ispire Technology reported a Q2 GAAP EPS of -$0.12, indicating ongoing challenges in profitability, which reflects the increasing market pressures and competition the company faces.
- Significant Revenue Decline: The reported revenue of $20.29 million represents a 51.5% year-over-year decrease, missing expectations by $12.51 million, a situation that could undermine investor confidence and negatively impact future financing capabilities.
- Cash Flow Position: As of December 31, 2025, Ispire held $17.6 million in cash and $3.5 million in working capital; while the cash reserves are adequate, ongoing losses may limit future operational flexibility and growth potential.
- Market Reaction Outlook: Given the poor financial performance, the market is expected to adopt a cautious stance towards Ispire's future prospects, potentially leading to increased stock price volatility, prompting investors to closely monitor the company's subsequent strategic adjustments and market responses.
See More
Ispire Technology Reports Key Financial Highlights for Q2 2026
- Significant Accounts Receivable Reduction: As of December 31, 2025, Ispire's net accounts receivable decreased by 19.5% to $37.9 million from $47.0 million at the end of fiscal 2025, demonstrating the company's success in managing high-quality customers and enhancing financial flexibility.
- Revenue and Gross Profit Decline: The revenue for Q2 2026 was $20.3 million, a substantial drop from $41.8 million in the same period last year, primarily due to a strategic shift away from lower-quality customers, resulting in decreased overall product sales and a gross margin decline from 18.5% to 17.1%.
- Operating Expenses Significantly Lowered: The company reported operating expenses of $10.3 million in Q2, down from $15.1 million, highlighting the effectiveness of its cost control measures, which lay a solid foundation for future profitability.
- Strong Cash Position: Ispire held $17.6 million in cash as of December 31, 2025, indicating financial stability in ongoing investments and operations, thereby supporting future growth initiatives.
See More
Ispire Technology Reports Q2 Fiscal 2026 Financial Results
- Revenue Decline: Ispire reported revenue of $20.3 million for Q2 FY2026, a significant 51.5% decrease from $41.8 million in Q2 FY2025, reflecting the company's strategic shift away from lower-quality customers, resulting in reduced overall product sales.
- Gross Profit and Margin: The gross profit for the quarter was $3.5 million with a gross margin of 17.1%, down from $7.7 million and 18.5% in the prior year, primarily due to a change in product mix with fewer high-margin products sold.
- Operating Expense Control: Total operating expenses decreased from $15.1 million in Q2 FY2025 to $10.3 million in Q2 FY2026, highlighting significant progress in cost control initiatives that enhance financial flexibility.
- Accounts Receivable Reduction: As of December 31, 2025, Ispire's net accounts receivable decreased by 19.5% to $37.9 million from $47.0 million as of June 30, 2025, indicating the company's ongoing focus on improving customer quality.
See More
Ispire Technology to Participate in 38th Annual ROTH Conference
- Conference Participation: Ispire Technology will participate in the 38th Annual ROTH Conference from March 22-24, 2026, in Dana Point, California, showcasing its innovations in vaping technology and precision dosing.
- Management Team Engagement: The company's management team will hold a fireside chat on March 23 at 8:00 a.m. PT in Blue-Consumer-Salon 2, aiming to engage with investors on the company's strategic development and market outlook.
- Global Patent Portfolio: Ispire owns or has filed over 200 patents globally, covering the research, development, and commercialization of e-cigarettes and cannabis vaping products, highlighting its technological leadership in the industry.
- Market Expansion Plans: Ispire's tobacco products are marketed worldwide, and the company has recently commenced marketing activities in Canada and Europe, further expanding its international market share.
See More
Ispire Technology to Participate in 38th Annual ROTH Conference
- Management Participation: Ispire Technology's management team will participate in the 38th Annual ROTH Conference from March 22-24, 2026, in Dana Point, California, showcasing innovations in vaping technology and precision dosing to enhance the company's visibility and credibility among investors.
- Fireside Chat Details: The management team will hold a fireside chat on March 23, 2026, at 8:00 a.m. PT, providing a direct interaction opportunity with investors, thereby strengthening communication and connections with potential investors.
- Global Patent Portfolio: Ispire owns or has filed over 200 patents related to the research, development, and commercialization of e-cigarettes and cannabis vaping products, indicating the company's technological leadership in the industry and laying the groundwork for future market expansion.
- Market Expansion Plans: Ispire's tobacco products are marketed globally, with restrictions in the U.S., China, and Russia, yet the company has initiated marketing activities in Canada and Europe, demonstrating a proactive approach to its internationalization strategy.
See More
Hospital and Medical Practitioners Stocks Decline
- Market Underperformance: On Tuesday, hospital and medical practitioners' stocks collectively fell by approximately 1.2%, indicating a decline in market confidence in the sector, which could negatively impact long-term investor expectations.
- AdaptHealth Leads Decline: AdaptHealth's stock plummeted by about 13.6%, making it the worst performer in the industry, suggesting potential operational or financial challenges that could affect its market share.
- Centene Pressured: Centene's stock decreased by approximately 3.5%, and although the drop is smaller, it still reflects market concerns regarding its future growth, potentially prompting investors to reassess their investment strategies.
- Industry Trend Warning: The overall decline in the healthcare sector may signal broader economic issues, prompting investors to monitor relevant policy changes and market dynamics to adjust their portfolios accordingly.
See More
Ispire Technology Q2 Earnings Report Analysis
- Poor Earnings Performance: Ispire Technology reported a Q2 GAAP EPS of -$0.12, indicating ongoing challenges in profitability, which reflects the increasing market pressures and competition the company faces.
- Significant Revenue Decline: The reported revenue of $20.29 million represents a 51.5% year-over-year decrease, missing expectations by $12.51 million, a situation that could undermine investor confidence and negatively impact future financing capabilities.
- Cash Flow Position: As of December 31, 2025, Ispire held $17.6 million in cash and $3.5 million in working capital; while the cash reserves are adequate, ongoing losses may limit future operational flexibility and growth potential.
- Market Reaction Outlook: Given the poor financial performance, the market is expected to adopt a cautious stance towards Ispire's future prospects, potentially leading to increased stock price volatility, prompting investors to closely monitor the company's subsequent strategic adjustments and market responses.
See More
Ispire Technology Reports Key Financial Highlights for Q2 2026
- Significant Accounts Receivable Reduction: As of December 31, 2025, Ispire's net accounts receivable decreased by 19.5% to $37.9 million from $47.0 million at the end of fiscal 2025, demonstrating the company's success in managing high-quality customers and enhancing financial flexibility.
- Revenue and Gross Profit Decline: The revenue for Q2 2026 was $20.3 million, a substantial drop from $41.8 million in the same period last year, primarily due to a strategic shift away from lower-quality customers, resulting in decreased overall product sales and a gross margin decline from 18.5% to 17.1%.
- Operating Expenses Significantly Lowered: The company reported operating expenses of $10.3 million in Q2, down from $15.1 million, highlighting the effectiveness of its cost control measures, which lay a solid foundation for future profitability.
- Strong Cash Position: Ispire held $17.6 million in cash as of December 31, 2025, indicating financial stability in ongoing investments and operations, thereby supporting future growth initiatives.
See More
Ispire Technology Reports Q2 Fiscal 2026 Financial Results
- Revenue Decline: Ispire reported revenue of $20.3 million for Q2 FY2026, a significant 51.5% decrease from $41.8 million in Q2 FY2025, reflecting the company's strategic shift away from lower-quality customers, resulting in reduced overall product sales.
- Gross Profit and Margin: The gross profit for the quarter was $3.5 million with a gross margin of 17.1%, down from $7.7 million and 18.5% in the prior year, primarily due to a change in product mix with fewer high-margin products sold.
- Operating Expense Control: Total operating expenses decreased from $15.1 million in Q2 FY2025 to $10.3 million in Q2 FY2026, highlighting significant progress in cost control initiatives that enhance financial flexibility.
- Accounts Receivable Reduction: As of December 31, 2025, Ispire's net accounts receivable decreased by 19.5% to $37.9 million from $47.0 million as of June 30, 2025, indicating the company's ongoing focus on improving customer quality.
See More
